Next Article in Journal
Back to the Origins: Background and Perspectives of Grapevine Domestication
Previous Article in Journal
In Silico Analysis of the Molecular-Level Impact of SMPD1 Variants on Niemann-Pick Disease Severity
Previous Article in Special Issue
Mitochondria and Pharmacologic Cardiac Conditioning—At the Heart of Ischemic Injury
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 9
10.3390/ijms22094517
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Combination of Cyclosporine A and Levosimendan Induces Cardioprotection under Acute Hyperglycemia

by
Carolin Torregroza
1,
Birce Yueksel
1,
Raphael Ruske
1,
Martin Stroethoff
1,
Annika Raupach
1,
André Heinen
2,
Markus W. Hollmann
3,
Ragnar Huhn
1,* and
Katharina Feige
1
1
Department of Anesthesiology, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany
2
Institute of Cardiovascular Physiology, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Universitaetsstr. 1, 40225 Duesseldorf, Germany
3
Department of Anesthesiology, Amsterdam University Medical Center (AUMC), Location AMC, Meiberdreef 9, 1105 AZ Amsterdam, The Netherlands
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(9), 4517; https://doi.org/10.3390/ijms22094517
Submission received: 10 March 2021 / Revised: 23 April 2021 / Accepted: 23 April 2021 / Published: 26 April 2021
(This article belongs to the Special Issue Pharmacological Conditioning of the Heart-Molecular Targets)
Browse Figures
Versions Notes

Abstract

:
Prognosis of patients with myocardial infarction is detrimentally affected by comorbidities like diabetes mellitus. In the experimental setting, not only diabetes mellitus but also acute hyperglycemia is shown to hamper cardioprotective properties by multiple pharmacological agents. For Levosimendan-induced postconditioning, a strong infarct size reducing effect is demonstrated in healthy myocardium. However, acute hyperglycemia is suggested to block this protective effect. In the present study, we investigated whether (1) Levosimendan-induced postconditioning exerts a concentration-dependent effect under hyperglycemic conditions and (2) whether a combination with the mitochondrial permeability transition pore (mPTP) blocker cyclosporine A (CsA) restores the cardioprotective properties of Levosimendan under hyperglycemia. For this experimental investigation, hearts of male Wistar rats were randomized and mounted onto a Langendorff system, perfused with Krebs-Henseleit buffer with a constant pressure of 80 mmHg. All isolated hearts were subjected to 33 min of global ischemia and 60 min of reperfusion under hyperglycemic conditions. (1) Hearts were perfused with various concentrations of Levosimendan (Lev) (0.3–10 μM) for 10 min at the onset of reperfusion, in order to investigate a concentration–response relationship. In the second set of experiments (2), 0.3 μM Levosimendan was administered in combination with the mPTP blocker CsA, to elucidate the underlying mechanism of blocked cardioprotection under hyperglycemia. Infarct size was determined by tetrazolium chloride (TTC) staining. (1) Control (Con) hearts showed an infarct size of 52 ± 12%. None of the administered Levosimendan concentrations reduced the infarct size (Lev0.3: 49 ± 9%; Lev1: 57 ± 9%; Lev3: 47 ± 11%; Lev10: 50 ± 7%; all ns vs. Con). (2) Infarct size of Con and Lev0.3 hearts were 53 ± 4% and 56 ± 2%, respectively. CsA alone had no effect on infarct size (CsA: 50 ± 10%; ns vs. Con). The combination of Lev0.3 and CsA (Lev0.3 ± CsA) induced a significant infarct size reduction compared to Lev0.3 (Lev0.3+CsA: 35 ± 4%; p < 0.05 vs. Lev0.3). We demonstrated that (1) hyperglycemia blocks the infarct size reducing effects of Levosimendan-induced postconditioning and cannot be overcome by an increased concentration. (2) Furthermore, cardioprotection under hyperglycemia can be restored by combining Levosimendan and the mPTP blocker CsA.

1. Introduction

Myocardial infarction (MI) usually presents as an unforeseeable event that is still associated with high rates of mortality and morbidity [1,2]. Even after survival of MI, patients are faced with a substantial risk of subsequent cardiovascular events, including sudden cardiac arrest or heart failure [3]. Prognosis after suffering from MI widely varies among patients and is immensely affected by comorbidities like hypertension or diabetes [4,5]. Interestingly, hyperglycemia seems to be an independent outcome-related risk factor for MI in patients with or without diabetes [6,7,8].
Restoration of coronary blood circulation is essential for all patients suffering from MI [9]; however, the paradoxically occurring ischemia-reperfusion (I/R) injury hampers the benefits of reperfusion. I/R injury is characterized as additional cell damage and death caused by restored blood supply to an ischemic organ or tissue, like the myocardium [10]. Hence, cardioprotective interventions protecting the heart against harmful consequences of I/R injury are fundamental. Considering the fact that MI—as an acute event—is mostly unpredictable, cardioprotective approaches performed after the occurrence of ischemia and subsequent I/R injury gain increasing relevance. Zhao et al. [11] described the mechanism of ischemic postconditioning (PoC), where short cycles of ischemia and reperfusion after a prolonged ischemic period induced a significant myocardial protection. Fortunately, a less invasive practice—administration of pharmacological agents—can mimic ischemic PoC. Different substances were demonstrated to confer myocardial protection, e.g., sedatives [12], opioids [13], or the calcium (Ca2+) sensitizer—Levosimendan [14,15].
In a clinical setting, Levosimendan is indicated for the treatment of acute and chronic heart failure, significantly lowering mortality when administered preoperatively, with the benefit of having positive inotropic characteristics without affecting the diastolic function [16]. The molecular background of Levosimendan relates to its specific interaction with cardiac troponin C in myofilaments, resulting in an increased sensitivity for Ca2+ in cardiomyocytes [17]. Experimental studies suggest that Levosimendan-induced conditioning is mediated via activation of mitochondrial potassium (mK+) channels [15,18,19] and phosphatidylinositol 3-kinase (PI3K) [20], ultimately causing a decrease of infarct size and improved cardiac function after I/R injury [15,21].
However, various comorbidities abolish cardioprotection induced by ischemic and pharmacological postconditioning [22,23,24]. In particular, acute hyperglycemia—which is frequently observed in patients with cardiovascular diseases—blocks several known conditioning strategies [24,25,26,27,28]. In line with these findings, Matsumoto et al. demonstrated that hyperglycemia raised the threshold for postconditioning with Levosimendan in vivo. A ten times higher concentration of Levosimendan was needed to restore the cardioprotective effect [29]. Authors suggest an involvement of known cardioprotective targets, like mK+ channels or the mitochondrial permeability transition pore (mPTP), in the hyperglycemia-induced blockade. However, definite evidence is lacking to this point. The mitochondria are thought to be the end-effector of cardioprotection [30,31] and the mPTP is considered to be the most integral player [32,33]. Opening of the mPTP ultimately leads to matrix swelling and cell death caused by the release of proapoptotic factors [34]. Referring to the influence of hyperglycemia, Huhn et al. [22] demonstrated that applying the mPTP inhibitor cyclosporine A (CsA) fully restores Sevoflurane-induced postconditioning, under elevated glucose levels.
Therefore, in this study, we set out to determine whether (1) acute hyperglycemia influences concentration-dependent postconditioning with Levosimendan and (2) if the combination with CsA reverses the hyperglycemia-caused loss of cardioprotection by Levosimendan.

2. Results

2.1. Animal Characteristics

Regarding body weight, wet and dry weight, and level or time of maximal contracture, no differences were detected between groups in both parts of this study (Table 1). For part 2 of the study, one dropout had to be reported in the Con group. The experiment was excluded from the study as it did not meet the baseline hemodynamic criteria (low baseline heart rate). Referring to the onset of maximal ischemia contracture, no differences were detected between the experimental groups. These results illustrate that myocardial damage caused by global ischemia was comparable between all study groups, underlining that differences in infarct size resulted from the respective postconditioning stimulus and not by varying the myocardial ischemic damage.

2.2. Infarct Size

Infarct sizes of part 1 of the study are shown in Figure 1. Infarct size of control hearts was 52 ± 12%. Levosimendan (Lev) in a concentration of 0.3 µM did not reduce infarct size under hyperglycemia (Lev0.3: 49 ± 9%; ns vs. Con). Increasing Levosimendan concentration also did not induce infarct size reduction (Lev1: 57 ± 9%; Lev3: 47 ± 11%; Lev10: 50 ± 7%; all ns vs. Con).
All infarct sizes investigated in part 2 are displayed in Figure 2. Control and Lev0.3 hearts showed infarct sizes of 53 ± 4% and 56 ± 2% of the left ventricle, respectively. Combining Lev0.3 with the mPTP blocker CsA (Lev0.3 ± CsA) significantly reduced the infarct size compared to Lev0.3 (Lev0.3+CsA: 35 ± 4%; p < 0.05 vs. Lev0.3). The mPTP blocker itself had no effect on infarct size (CsA: 50 ± 10%; ns vs. Con).

2.3. Cardiac Function

In part 1 of the study, no differences were observed between the groups at the different measurement time-points. Heart rate remained stable throughout the whole experimental protocol. A significant decrease during reperfusion compared to baseline was detected for both left ventricular, which developed pressure and coronary flow values within each group. All hemodynamic variables from part 1 can be found in Table 2.
Table 3 displays all hemodynamic variables from part 2 of the study. Again, no differences were detected between the different groups for any given time-point of measurement. Comparable to part 1 of the study, during reperfusion pressure and coronary flow that developed in the left ventricular decreased significantly, as compared to the baseline within each study group.

2.4. Glucose Levels

All glucose levels are displayed in Table 4. Compared to baseline, all groups showed a significant increase in glucose values (hyperglycemia). For part 1 and 2 of the study, there were no differences in glucose concentration between the individual groups.

3. Discussion

In the present study, we focused on the influence of hyperglycemia on postconditioning with Levosimendan and whether increased concentrations or combined inhibition of mPTP could overcome a potential loss of cardioprotection. Our results demonstrated that (1) acute hyperglycemia fully abrogated Levosimendan-induced postconditioning even under increased substance concentrations. However, (2) combining the mPTP blocker CsA and Levosimendan restored cardioprotection under acute hyperglycemia.

3.1. Influence of Hyperglycemia on Levosimendan-Induced Postconditioning

Acute hyperglycemia is not only considered an independent risk factor of cardiovascular diseases, like MI, but also significantly influences morbidity and mortality after occurrence of ischemia and reperfusion [4,6,8]. More importantly, elevated glucose levels crucially interfered with several ischemic and pharmacological conditioning strategies in experimental studies [24,35,36]. This might be one explanation for the remaining challenge of successfully translating cardioprotective approaches into the clinical setting [37,38]. Therefore, unraveling the influence of hyperglycemia on conditioning strategies is of considerable importance.
In a previous study, we demonstrated a concentration-related cardioprotective effect of postconditioning by Levosimendan [14]. We detected an on–off phenomenon, which was either ineffective or had maximal effect under normoglycemic conditions. A concentration of 0.3 μM Levosimendan as postconditioning stimulus induced cardioprotection, whereas an increase to 1 μM had no additional effect. Results from our own and other studies indicate that Levosimendan-induced postconditioning is mainly mediated via the reperfusion injury salvage kinase (RISK) pathway [18,20]. In more detail, mitochondrial adenosine triphosphate (ATP)-sensitive potassium (mKATP) and large conductance calcium-sensitive potassium (mBKCa) channels are suggested to be main downstream targets of cardioprotection by Levosimendan [14,15,19,20]. All of these targets are possibly blunted by elevated glucose levels [23,39,40].
Previous studies on hyperglycemia and ischemic or pharmacological conditioning indicated that the loss of cardioprotection can be reversed by increased stimuli. In an in vitro I/R animal study, one cycle of ischemic preconditioning did not reduce infarct size, while three cycles of the same stimulus did confer cardioprotection in diabetic myocardium [41]. The same holds true for pharmacological preconditioning with increased concentrations of Isoflurane [42].
Matsumoto et al. [29] previously demonstrated that hyperglycemia blocks postconditioning with Levosimendan in vivo, presumably due to a raised threshold for cardioprotection. This explanation was based on findings that increased concentration of Levosimendan did indeed induce infarct size reduction under elevated glucose levels. However, a ten times higher concentration was needed to achieve cardioprotection. In contrary to these results, in our present study even increased concentration did not induce cardioprotection under hyperglycemia in vitro. A possible explanation might be the different experimental settings. Matsumoto et al. employed an in vivo I/R animal model, while our experiments were performed in isolated hearts in vitro. We chose this setting to exclude possible systemic influences of other organs or hormones. Furthermore, our study involved hyperglycemia throughout the whole 60 min reperfusion phase. In contrast, Matsumoto et al. applied the glucose solution only during the first half of reperfusion, with a total of 120 min reperfusion phase. These differences in experimental protocol as well as possible systemic influences in vivo vs. in vitro might explain the contrary findings in our present study.
Nevertheless, increasing concentrations of Levosimendan to overcome blocked protection by hyperglycemia might not be advisable for patients. We showed that 0.3 µM was the lowest cardioprotective concentration of Levosimendan under normoglycemia in vitro. This converted to around 100 µg/L which was in line with the detected plasma concentrations (10–100 µg/L) under clinical dosage of Levosimendan [43,44,45]. However, it was already situated at the higher end of the therapeutic dose range. Considering adverse effects, applying a ten times higher concentration of Levosimendan under hyperglycemia does not seem practical in the clinical setting. Thus, increased dosage to restore blocked cardioprotection through hyperglycemia might not be feasible for Levosimendan-induced postconditioning.

3.2. Reversing the Loss of Levosimendan-Induced Cardioprotection under Hyperglycemia by Combined Treatment with CsA

From the literature, it is well-known that acute hyperglycemia attenuates cardioprotection; however, detailed explanation of possible underlying mechanisms is still lacking. Studies indicate that hyperglycemia leads to elevated ATP levels, which in turn hampers activation of the mKATP channels [39,46,47]. Next to ATP, excessive levels of reactive oxygen species (ROS) were detected under hyperglycemic conditions [48]. While ROS are essential in conferring cardioprotection, disproportional amounts ultimately cause opening of the mPTP and thus cell death [30,49]. Acute hyperglycemia not only has a negative impact on the mKATP channels but also blocks different parts of cardioprotective signaling cascades, for example, Akt phosphorylation, nitric oxide (NO), endothelial NO synthase (eNOS), or protein kinase G (PKG) [23,25,50,51]. Some of these respective targets are crucially involved in Levosimendan-induced cardioprotection. Especially, regulation of mitochondrial bioenergetics through mK+ channels and mPTP seems to play an integral role in conditioning strategies, under hyperglycemia [39]. Matsumoto et al. [29] demonstrated blocked postconditioning with Levosimendan under elevated glucose levels, while Milrinone was still effective. They presented involvement of different mK+ channels as a possible explanation for this discrepancy. Levosimendan is mediated via both mBKCa and mKATP channels [14,18]. Milrinone, however, is supposedly only dependent on mBKCa channels. Both substances ultimately target the mPTP and the protective properties could be fully abolished by administration of the mPTP activator atractyloside [29]. Taking together all these findings, it could be assumed that regulation of mitochondrial function, in particular mKATP channels, ROS levels and mPTP, play an integral role in lost cardioprotective properties of Levosimendan, under hyperglycemic conditions.
Multitarget strategies, meaning combination of substances or conditioning approaches, were the main research focus in the context of overcoming challenges in translating cardioprotection into clinical trials [52]. Next to the above-mentioned increased stimulus or concentration, combined conditioning strategies were shown to restore cardioprotection under hyperglycemia. Kehl et al. demonstrated that hyperglycemia blocks Isoflurane-preconditioning, but combination with the ROS scavenger N-acetylcystein restores the cardioprotective effects [50]. These findings further underline the importance of ROS in hyperglycemia. Interestingly and in line with our findings, cardioprotection with Sevoflurane is completely abrogated under acute hyperglycemia. However, inhibiting mPTP opening by administration of CsA, reversed the loss of protective effects [22]. Similar to our results, Huhn et al. [22] demonstrated that applying CsA individually did not restore cardioprotection under hyperglycemia. Even though inhibition of mPTP opening with CsA was shown to protect healthy myocardium [53,54], elevated glucose levels seemed to interfere with these properties. Further, they also demonstrated that an increased concentration of CsA did not overcome the hyperglycemia-induced loss of cardioprotection. These findings indicate that a pharmacological stimulus could possibly amplify the inhibition of mPTP with CsA and thus induce cardioprotection, even under hyperglycemia. Another possible explanation might be a lowered threshold for cardioprotection by combining stimuli triggering different pathways. Our results were consistent with findings from Huhn et al. on Sevoflurane and CsA [22]. In this study and to our knowledge for the first time, we demonstrated that while hyperglycemia blocks pharmacological conditioning with Levosimendan, this loss of cardioprotection could be restored with co-administration of CsA.

3.3. Limitations

While our results showed a significant infarct size reduction by combining Levosimendan and CsA under acute hyperglycemia, no hemodynamic improvement was detected during reperfusion, as compared to the other study groups. The concept of myocardial stunning after global ischemia might explain these rather contradictory findings. Myocardial stunning is defined as a temporary depression of function in the surviving myocardial tissue, which occurs especially after global ischemia. Even a prolonged reperfusion phase (up to 120 min) only displayed slight changes in hemodynamic data—insufficient for assessment of heart function—with no further impact on infarct size reduction [55]. Consistent with current literature, measurement of infarct size still represents the most sensitive marker to access cardioprotection in the isolated heart [56]. Based on these aspects, we chose the respective experimental protocol of our study.
Furthermore, we did not conduct experiments investigating the underlying mechanisms of restored cardioprotection by combining Levosimendan and CsA under hyperglycemia. Whether beneficial effects by simultaneous treatment were achieved by a lowered threshold of the same mitochondrial end-effector or parallel activation of different signaling pathways, remains an open question at this point. Investigating these exact underlying mechanisms were beyond the scope of our current study. Further research is needed to unravel whether mPTP is completely blocked by combining Levosimendan and CsA or if other pathways are involved.
Lastly, due to animal ethical reasons, we refrained from including normoglycemic control groups. We [14] and others [18] previously demonstrated that Levosimendan-induced postconditioning significantly reduced infarct size in healthy isolated hearts. Moreover, our own research group investigated the underlying mechanisms of postconditioning with Levosimendan by employing the exact same experimental setup. Stroethoff et al. demonstrated that Levosimendan-induced postconditioning reduced infarct size by about −50%, as compared to a normoglycemic control group [14]. Hence, these previous results could be referenced for normoglycemic groups, in the context of Levosimendan-induced postconditioning.

4. Materials and Methods

All experiments included in this study were conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institute of Health (NIH publication No.85-23, revised 1996). Investigations were approved by the local Animal Care and Use Committee of the University of Duesseldorf (project number O27/12), and results were reported according to the ARRIVE guidelines.

4.1. Surgical Preparation

The surgical preparation was performed as described in detail previously [57]. Male wistar rats (2–3-month-old) were anesthetized with intraperitoneal injection of pentobarbital (80 mg/kg body weight, Narcoren, Merial, Germany) and decapitated. Hearts were resected via a thoracotomy, mounted onto a Langendorff-System (built in-house) and perfused with Krebs-Henseleit-Buffer (KHB) (Chemicals sourced from Sigma-Aldrich, Germany; KHB solution prepared in-house) enriched with a mixture of 95% O2 and 5% CO2. The KHB solution contained 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.17 mM KH2PO4, 24.9 mM NaHCO3, 2.52 mM CaCl2, 11 mM glucose, and 1 mM lactate, and was perfused under constant pressure (80 mmHg) and temperature (37 °C). For hemodynamic measurements, a fluid-filled balloon (manufactured in-house) was inserted into the left ventricle, setting left ventricular end-diastolic pressure to 4–6 mmHg. For all experiments, heart rate, left ventricular end-systolic pressure (LVESP), left ventricular end-diastolic pressure (LVEDP), and coronary flow (CF) were continuously measured and digitized by an analogue to digital converter (PowerLab/8SP, ADInstruments Pty Ltd., Castle Hill, Australia), at a sampling rate of 500 Hz. LVESP and LVEDP values allowed for calculation of left ventricular developed pressure (LVDP) (LVDP = LVESP − LVEDP). As a possible indicator for differences in myocardial injury, we analyzed the level and time-point of maximal contracture during ischemia for each experiment. To examine infarct size, after successful completion of the protocol, each heart was removed and cut into 8 transverse slices (2 mm each slice). Afterwards, a 0.75% triphenyltetrazoliumchloride (TTC) solution was applied to detect the infarcted area as compared to viable tissue. A blinded, experienced investigator analyzed infarct sizes using planimetry (SigmaScan Pro5 software), determined as the percentage of infarct area per total area of the left ventricle [58].

4.2. Experimental Protocol

The study consisted of two separate parts. For both parts, we employed the same basic experimental protocol (shown in Figure 3 and Figure 4). All hearts underwent 15 min of adaption period. Hereafter, acute hyperglycemia was induced in all hearts, 5 min prior to global ischemia, by applying a 11 mmol/L glucose solution consistently throughout the entire experiment. As KHB itself already contained 11 mmol/L glucose, a total of 22 mmol/L glucose was reached in all hearts. All investigations included in this study were carried out following the same protocol for induction of acute hyperglycemia. This concentration was proven to block different pharmacological conditioning strategies by us and others [22,24,35,42]. Glucose levels were frequently reevaluated throughout each experiment, by collecting coronary effluent. The current protocol was taken from our previous study, where we successfully induced acute hyperglycemia in isolated hearts [24]. Global ischemia was followed by 60 min of, including a 10 min postconditioning (PoC) period. For all experiments, global ischemia was achieved by completely stopping the perfusion to the heart via the Langendorff System. We administered the respective substance for 10 min, starting immediately at the onset of reperfusion, to achieve a postconditioning stimulus. All substances were applied at an infusion rate of 1% of coronary flow. The applied concentration of all substances in our current study were shown to be effective in several previous studies [14,59].

4.2.1. Part 1: Concentration–Response Relationship of Levosimendan under Hyperglycemia

For part 1, animals were randomly assigned into 5 experimental groups (n = 7 per group), as shown in Figure 1. The first part was designed to investigate a possible concentration-dependent effect of Levosimendan under acute hyperglycemia. In previous studies, we demonstrated 0.3 µM as the lowest cardioprotective concentration of Levosimendan under normoglycemic conditions [14,19]. Therefore, we further increased Levosimendan concentrations to 1 µM, 3 µM, and 10 µM. Levosimendan was applied under hyperglycemic conditions as a postconditioning stimulus for 10 min after ischemia.

4.2.2. Part 2: Underlying Mechanisms of Levosimendan-Induced Postconditioning under Hyperglycemia

The second part of this study was designed to elucidate the potentially underlying mechanism of blocked cardioprotection by Levosimendan, under acute hyperglycemia. Previously, we demonstrated a strong cardioprotective effect by postconditioning with 0.3 µM Levosimendan under normoglycemia, whereas higher concentrations did not further enhance the protective effect [14]. Based on these findings and results from part 1 of this study, we employed 0.3 µM Levosimendan as a postconditioning stimulus for investigations in part 2. Concentration of the mPTP inhibitor CsA was taken from the literature [59,60]. All substances were administered under hyperglycemic conditions as a postconditioning stimulus for 10 min. In part 2, hearts were randomized into 4 groups (n = 5 per group).

4.3. Statistical Analysis

4.3.1. Sample Size Analysis

A sample size of n = 7 (part 1) and n = 5 (part 2) was calculated (GraphPad StatMate™, GraphPad Software, San Diego, CA, USA), detecting a 25% mean difference in infarct size (power 80%, α < 0.05 (two-tailed)).

4.3.2. Statistical Approach

Both parts of the study were analyzed separately, each by performing a two-way analysis of variance (ANOVA) and a Tukey post-hoc test (GraphPad Software V7.01, San Diego, CA, USA) for hemodynamic data between groups and time-effects within each group. For part 1 and 2, infarct sizes were analyzed by a one-way ANOVA, followed by a Tukey’s post-hoc test. Data are expressed as mean ± standard deviation (SD). Changes were considered to be statistically significant if p < 0.05.

5. Conclusions

Our findings demonstrate that Levosimendan-induced postconditioning is completely abolished under hyperglycemia. Applying increased Levosimendan concentrations could not overcome blocked cardioprotective effects by hyperglycemia in this experimental setting. While inhibition of mPTP by CsA alone could not restore infarct size reduction under hyperglycemia, combining Levosimendan and CsA reversed the loss of cardioprotection under elevated glucose levels.

Author Contributions

Conceptualization, C.T., K.F., and R.H.; methodology, C.T., K.F., A.R., and M.S.; formal analysis, C.T., M.S. and R.H.; investigation, B.Y., R.R., and A.R.; writing—original draft preparation, C.T. and K.F.; writing—review and editing, A.H., M.W.H., and R.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals and investigations were approved by the local Animal Care and Use Committee of the University of Duesseldorf (project number O27/12).

Informed Consent Statement

Not applicable.

Acknowledgments

In partial fulfillment of the requirements for an MD thesis of Birce Yueksel and Raphael Ruske.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kayani, W.T.; Ballantyne, C.M. Improving Outcomes after Myocardial Infarction in the US Population. J. Am. Heart Assoc. 2018, 7, e008407. [Google Scholar] [CrossRef] [Green Version]
  2. World Health Organization. The 10 Leading Causes of Death in the World, 2000 and 2012. Available online: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed on 9 March 2021).
  3. Ko, D.T.; Khera, R.; Lau, G.; Qiu, F.; Wang, Y.; Austin, P.C.; Koh, M.; Lin, Z.; Lee, D.S.; Wijeysundera, H.C.; et al. Readmission and Mortality After Hospitalization for Myocardial Infarction and Heart Failure. J. Am. Coll. Cardiol. 2020, 75, 736–746. [Google Scholar] [CrossRef]
  4. Deckers, J.W.; van Domburg, R.T.; Akkerhuis, M.; Nauta, S.T. Relation of admission glucose levels, short- and long-term (20-year) mortality after acute myocardial infarction. Am. J. Cardiol. 2013, 112, 1306–1310. [Google Scholar] [CrossRef] [PubMed]
  5. Jelesoff, N.E.; Feinglos, M.; Granger, C.B.; Califf, R.M. Outcomes of diabetic patients following acute myocardial infarction: A review of the major thrombolytic trials. Coron. Artery Dis. 1996, 7, 732–743. [Google Scholar] [CrossRef]
  6. Bellodi, G.; Manicardi, V.; Malavasi, V.; Veneri, L.; Bernini, G.; Bossini, P.; Distefano, S.; Magnanini, G.; Muratori, L.; Rossi, G.; et al. Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. Am. J. Cardiol. 1989, 64, 885–888. [Google Scholar] [CrossRef]
  7. Wei, C.H.; Litwin, S.E. Hyperglycemia and Adverse Outcomes in Acute Coronary Syndromes: Is Serum Glucose the Provocateur or Innocent Bystander? Diabetes 2014, 63, 2209–2212. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Goyal, A.; Mehta, S.R.; Díaz, R.; Gerstein, H.C.; Afzal, R.; Xavier, D.; Liu, L.; Pais, P.; Yusuf, S. Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. Circulation 2009, 120, 2429–2437. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Roe, M.T.; Messenger, J.C.; Weintraub, W.S.; Cannon, C.P.; Fonarow, G.C.; Dai, D.; Chen, A.Y.; Klein, L.W.; Masoudi, F.A.; McKay, C.; et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J. Am. Coll. Cardiol. 2010, 56, 254–263. [Google Scholar] [CrossRef] [PubMed]
  10. Hausenloy, D.J.; Yellon, D.M. Myocardial ischemia-reperfusion injury: A neglected therapeutic target. J. Clin. Investig. 2013, 123, 92–100. [Google Scholar] [CrossRef] [PubMed]
  11. Zhao, Z.Q.; Corvera, J.S.; Halkos, M.E.; Kerendi, F.; Wang, N.P.; Guyton, R.A.; Vinten-Johansen, J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 2003, 285, H579–H588. [Google Scholar] [CrossRef] [PubMed]
  12. Bunte, S.; Behmenburg, F.; Majewski, N.; Stroethoff, M.; Raupach, A.; Mathes, A.; Heinen, A.; Hollmann, M.W.; Huhn, R. Characteristics of Dexmedetomidine Postconditioning in the Field of Myocardial Ischemia-Reperfusion Injury. Anesth. Analg. 2019. [Google Scholar] [CrossRef]
  13. Huhn, R.; Heinen, A.; Weber, N.C.; Schlack, W.; Preckel, B.; Hollmann, M.W. Ischaemic and morphine-induced post-conditioning: Impact of mK(Ca) channels. Br. J. Anaesth. 2010, 105, 589–595. [Google Scholar] [CrossRef] [Green Version]
  14. Stroethoff, M.; Bunte, S.; Raupach, A.; van de Snepscheut, M.; Torregroza, C.; Heinen, A.; Mathes, A.; Hollmann, M.W.; Huhn, R.; Sixt, S.U. Impact of Ca(2+)-Sensitive Potassium Channels in Levosimendan-Induced Postconditioning. Cardiovasc. Drugs 2019, 33, 581–588. [Google Scholar] [CrossRef]
  15. Kersten, J.R.; Montgomery, M.W.; Pagel, P.S.; Warltier, D.C. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth. Analg. 2000, 90, 5–11. [Google Scholar] [CrossRef]
  16. Levin, R.; Degrange, M.; Del Mazo, C.; Tanus, E.; Porcile, R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp. Clin. Cardiol. 2012, 17, 125–130. [Google Scholar]
  17. Papp, Z.; Édes, I.; Fruhwald, S.; De Hert, S.G.; Salmenperä, M.; Leppikangas, H.; Mebazaa, A.; Landoni, G.; Grossini, E.; Caimmi, P.; et al. Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan. Int. J. Cardiol. 2012, 159, 82–87. [Google Scholar] [CrossRef] [Green Version]
  18. du Toit, E.F.; Genis, A.; Opie, L.H.; Pollesello, P.; Lochner, A. A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br. J. Pharm. 2008, 154, 41–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Bunte, S.; Behmenburg, F.; Bongartz, A.; Stroethoff, M.; Raupach, A.; Heinen, A.; Minol, J.P.; Hollmann, M.W.; Huhn, R.; Sixt, S.U. Preconditioning by Levosimendan is Mediated by Activation of Mitochondrial Ca(2+)-Sensitive Potassium (mBKCa) Channels. Cardiovasc. Drugs 2018, 32, 427–434. [Google Scholar] [CrossRef]
  20. Hönisch, A.; Theuring, N.; Ebner, B.; Wagner, C.; Strasser, R.H.; Weinbrenner, C. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition. Basic Res. Cardiol. 2010, 105, 155–167. [Google Scholar] [CrossRef] [PubMed]
  21. Du Toit, E.F.; Muller, C.A.; McCarthy, J.; Opie, L.H. Levosimendan: Effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J. Pharm. Exp. 1999, 290, 505–514. [Google Scholar]
  22. Huhn, R.; Heinen, A.; Weber, N.C.; Hollmann, M.W.; Schlack, W.; Preckel, B. Hyperglycaemia blocks sevoflurane-induced postconditioning in the rat heart in vivo: Cardioprotection can be restored by blocking the mitochondrial permeability transition pore. Br. J. Anaesth. 2008, 100, 465–471. [Google Scholar] [CrossRef] [Green Version]
  23. Raphael, J.; Gozal, Y.; Navot, N.; Zuo, Z. Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase/Akt and endothelial nitric oxide synthase signaling. J. Cardiovasc. Pharm. 2010, 55, 348–357. [Google Scholar] [CrossRef] [PubMed]
  24. Torregroza, C.; Feige, K.; Schneider, L.; Bunte, S.; Stroethoff, M.; Heinen, A.; Hollmann, M.W.; Huhn, R.; Raupach, A. Influence of Hyperglycemia on Dexmedetomidine-Induced Cardioprotection in the Isolated Perfused Rat Heart. J. Clin. Med. 2020, 9, 1445. [Google Scholar] [CrossRef]
  25. Baranyai, T.; Nagy, C.T.; Koncsos, G.; Onodi, Z.; Karolyi-Szabo, M.; Makkos, A.; Varga, Z.V.; Ferdinandy, P.; Giricz, Z. Acute hyperglycemia abolishes cardioprotection by remote ischemic perconditioning. Cardiovasc. Diabetol. 2015, 14, 151. [Google Scholar] [CrossRef] [Green Version]
  26. Goergens, J.I.; Heinen, N.M.; Zoller, J.; Preckel, B.; Bauer, I.; Huhn, R.; Ebel, D.; Raupach, A. Influence of Hyperglycemia During Different Phases of Ischemic Preconditioning on Cardioprotection-A Focus on Apoptosis and Aggregation of Granulocytes. Shock 2019. [Google Scholar] [CrossRef]
  27. Kim, H.S.; Kim, S.Y.; Kwak, Y.L.; Hwang, K.C.; Shim, Y.H. Hyperglycemia attenuates myocardial preconditioning of remifentanil. J. Surg. Res. 2012, 174, 231–237. [Google Scholar] [CrossRef] [PubMed]
  28. Penna, C.; Andreadou, I.; Aragno, M.; Beauloye, C.; Bertrand, L.; Lazou, A.; Falcão-Pires, I.; Bell, R.; Zuurbier, C.J.; Pagliaro, P.; et al. Effect of hyperglycaemia and diabetes on acute myocardial ischaemia–reperfusion injury and cardioprotection by ischaemic conditioning protocols. Br. J. Pharmacol. 2020, 177, 5312–5335. [Google Scholar] [CrossRef]
  29. Matsumoto, S.; Cho, S.; Tosaka, S.; Higashijima, U.; Maekawa, T.; Hara, T.; Sumikawa, K. Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts. Cardiovasc. Diabetol. 2012, 11, 4. [Google Scholar] [CrossRef] [Green Version]
  30. Boengler, K.; Lochnit, G.; Schulz, R. Mitochondria “THE” target of myocardial conditioning. Am. J. Physiol. Heart Circ. Physiol. 2018, 315, H1215–H1231. [Google Scholar] [CrossRef] [Green Version]
  31. Lisa, F.D.; Canton, M.; Menabò, R.; Kaludercic, N.; Bernardi, P. Mitochondria and cardioprotection. Heart Fail. Rev. 2007, 12, 249–260. [Google Scholar] [CrossRef]
  32. Di Lisa, F.; Carpi, A.; Giorgio, V.; Bernardi, P. The mitochondrial permeability transition pore and cyclophilin D in cardioprotection. Biochim. Biophys. Acta (BBA) Mol. Cell Res. 2011, 1813, 1316–1322. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Hausenloy, D.J.; Yellon, D.M. The mitochondrial permeability transition pore: Its fundamental role in mediating cell death during ischaemia and reperfusion. J. Mol. Cell. Cardiol. 2003, 35, 339–341. [Google Scholar] [CrossRef] [Green Version]
  34. Torregroza, C.; Raupach, A.; Feige, K.; Hollmann, M.W.; Huhn, R. Perioperative Cardioprotection: General Mechanisms and Pharmacological Approaches. Anesth. Analg. 2020, 131, 1765–1780. [Google Scholar] [CrossRef]
  35. Kersten, J.R.; Schmeling, T.J.; Orth, K.G.; Pagel, P.S.; Warltier, D.C. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am. J. Physiol. 1998, 275, H721–H725. [Google Scholar] [CrossRef]
  36. Weber, N.C.; Goletz, C.; Huhn, R.; Grueber, Y.; Preckel, B.; Schlack, W.; Ebel, D. Blockade of anaesthetic-induced preconditioning in the hyperglycaemic myocardium: The regulation of different mitogen-activated protein kinases. Eur. J. Pharm. 2008, 592, 48–54. [Google Scholar] [CrossRef]
  37. Heusch, G. Critical Issues for the Translation of Cardioprotection. Circ. Res. 2017, 120, 1477–1486. [Google Scholar] [CrossRef] [Green Version]
  38. Roth, S.; Torregroza, C.; Huhn, R.; Hollmann, M.W.; Preckel, B. Perioperative Cardioprotection: Clinical Implications. Anesth. Analg. 2020, 131, 1751–1764. [Google Scholar] [CrossRef]
  39. Kersten, J.R.; Montgomery, M.W.; Ghassemi, T.; Gross, E.R.; Toller, W.G.; Pagel, P.S.; Warltier, D.C. Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, H1744–H1750. [Google Scholar] [CrossRef] [Green Version]
  40. Lei, S.; Su, W.; Xia, Z.Y.; Wang, Y.; Zhou, L.; Qiao, S.; Zhao, B.; Xia, Z.; Irwin, M.G. Hyperglycemia-Induced Oxidative Stress Abrogates Remifentanil Preconditioning-Mediated Cardioprotection in Diabetic Rats by Impairing Caveolin-3-Modulated PI3K/Akt and JAK2/STAT3 Signaling. Oxid. Med. Cell Longev. 2019, 2019, 9836302. [Google Scholar] [CrossRef]
  41. Tsang, A.; Hausenloy, D.J.; Mocanu, M.M.; Carr, R.D.; Yellon, D.M. Preconditioning the Diabetic Heart: The Importance of Akt Phosphorylation. Diabetes 2005, 54, 2360–2364. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Kehl, F.; Krolikowski, J.G.; Mraovic, B.; Pagel, P.S.; Warltier, D.C.; Kersten, J.R. Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction. Anesthesiology 2002, 96, 183–188. [Google Scholar] [CrossRef]
  43. Antila, S.; Sundberg, S.; Lehtonen, L.A. Clinical pharmacology of levosimendan. Clin. Pharm. 2007, 46, 535–552. [Google Scholar] [CrossRef]
  44. Harjola, V.-P.; Giannakoulas, G.; von Lewinski, D.; Matskeplishvili, S.; Mebazaa, A.; Papp, Z.; Schwinger, R.H.G.; Pollesello, P.; Parissis, J.T. Use of levosimendan in acute heart failure. Eur. Heart J. Suppl. 2018, 20, I2–I10. [Google Scholar] [CrossRef] [Green Version]
  45. Jonsson, E.N.; Antila, S.; McFadyen, L.; Lehtonen, L.; Karlsson, M.O. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br. J. Clin. Pharm. 2003, 55, 544–551. [Google Scholar] [CrossRef]
  46. Craig, T.J.; Ashcroft, F.M.; Proks, P. How ATP inhibits the open K(ATP) channel. J. Gen. Physiol. 2008, 132, 131–144. [Google Scholar] [CrossRef]
  47. Garlid, K.D.; Dos Santos, P.; Xie, Z.-J.; Costa, A.D.T.; Paucek, P. Mitochondrial potassium transport: The role of the mitochondrial ATP-sensitive K+ channel in cardiac function and cardioprotection. Biochim. Biophys. Acta (BBA) Bioenerg. 2003, 1606, 1–21. [Google Scholar] [CrossRef] [Green Version]
  48. Callaghan, M.J.; Ceradini, D.J.; Gurtner, G.C. Hyperglycemia-induced reactive oxygen species and impaired endothelial progenitor cell function. Antioxid. Redox Signal. 2005, 7, 1476–1482. [Google Scholar] [CrossRef]
  49. Costa, A.D.; Garlid, K.D. Intramitochondrial signaling: Interactions among mitoKATP, PKCepsilon, ROS, and MPT. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H874–H882. [Google Scholar] [CrossRef] [Green Version]
  50. Kehl, F.; Krolikowski, J.G.; Weihrauch, D.; Pagel, P.S.; Warltier, D.C.; Kersten, J.R. N-acetylcysteine restores isoflurane-induced preconditioning against myocardial infarction during hyperglycemia. Anesthesiology 2003, 98, 1384–1390. [Google Scholar] [CrossRef] [PubMed]
  51. Nakadate, Y.; Sato, H.; Oguchi, T.; Sato, T.; Kawakami, A.; Ishiyama, T.; Matsukawa, T.; Schricker, T. Glycemia and the cardioprotective effects of insulin pre-conditioning in the isolated rat heart. Cardiovasc. Diabetol. 2017, 16, 43. [Google Scholar] [CrossRef] [Green Version]
  52. Davidson, S.M.; Ferdinandy, P.; Andreadou, I.; Bøtker, H.E.; Heusch, G.; Ibáñez, B.; Ovize, M.; Schulz, R.; Yellon, D.M.; Hausenloy, D.J.; et al. Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 2019, 73, 89–99. [Google Scholar] [CrossRef] [PubMed]
  53. Argaud, L.; Gateau-Roesch, O.; Muntean, D.; Chalabreysse, L.; Loufouat, J.; Robert, D.; Ovize, M. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J. Mol. Cell. Cardiol. 2005, 38, 367–374. [Google Scholar] [CrossRef] [PubMed]
  54. Hausenloy, D.J.; Maddock, H.L.; Baxter, G.F.; Yellon, D.M. Inhibiting mitochondrial permeability transition pore opening: A new paradigm for myocardial preconditioning? Cardiovasc. Res. 2002, 55, 534–543. [Google Scholar] [CrossRef]
  55. Watanabe, M.; Okada, T. Langendorff Perfusion Method as an Ex Vivo Model to Evaluate Heart Function in Rats. Methods Mol. Biol. 2018, 1816, 107–116. [Google Scholar] [CrossRef]
  56. Ferrera, R.; Benhabbouche, S.; Bopassa, J.C.; Li, B.; Ovize, M. One hour reperfusion is enough to assess function and infarct size with TTC staining in Langendorff rat model. Cardiovasc. Drugs 2009, 23, 327–331. [Google Scholar] [CrossRef]
  57. Feige, K.; Rubbert, J.; Raupach, A.; Stroethoff, M.; Heinen, A.; Hollmann, M.W.; Huhn, R.; Torregroza, C. Cardioprotective Properties of Mannitol-Involvement of Mitochondrial Potassium Channels. Int. J. Mol. Sci. 2021, 22, 2395. [Google Scholar] [CrossRef]
  58. Behmenburg, F.; Dorsch, M.; Huhn, R.; Mally, D.; Heinen, A.; Hollmann, M.W.; Berger, M.M. Impact of Mitochondrial Ca2+-Sensitive Potassium (mBKCa) Channels in Sildenafil-Induced Cardioprotection in Rats. PLoS ONE 2015, 10, e0144737. [Google Scholar] [CrossRef]
  59. Stroethoff, M.; Goetze, L.; Torregroza, C.; Bunte, S.; Raupach, A.; Heinen, A.; Mathes, A.; Hollmann, M.W.; Huhn, R. The Melatonin Receptor Agonist Ramelteon Induces Cardioprotection that Requires MT2 Receptor Activation and Release of Reactive Oxygen Species. Cardiovasc. Drugs Ther. 2020, 34, 303–310. [Google Scholar] [CrossRef] [Green Version]
  60. Raupach, A.; Reinle, J.; Stroethoff, M.; Mathes, A.; Heinen, A.; Hollmann, M.W.; Huhn, R.; Bunte, S. Milrinone-Induced Pharmacological Preconditioning in Cardioprotection: Hints for a Role of Mitochondrial Mechanisms. J. Clin. Med. 2019, 8, 507. [Google Scholar] [CrossRef] [Green Version]
Ijms 22 04517 g001 550
Figure 1. Infarct size measurement part 1. Histogram shows all infarct sizes of the study. Data are presented as means ± SD.
Figure 1. Infarct size measurement part 1. Histogram shows all infarct sizes of the study. Data are presented as means ± SD.
Ijms 22 04517 g001
Ijms 22 04517 g002 550
Figure 2. Infarct size measurement part 2. Histogram shows all infarct sizes of the study. Data are presented as means ± SD, * p < 0.05 vs. Lev0.3.
Figure 2. Infarct size measurement part 2. Histogram shows all infarct sizes of the study. Data are presented as means ± SD, * p < 0.05 vs. Lev0.3.
Ijms 22 04517 g002
Ijms 22 04517 g003 550
Figure 3. Experimental protocol. Con = Control; Lev = Levosimendan, KHB = Krebs-Henseleit-Buffer; Vehicle = Krebs-Henseleit Buffer (KHB). Green bar: Hearts were perfused with a total of 22 mmol/L glucose concentration by combining 11 mmol/L glucose solution with KHB (containing 11 mmol/L glucose). Control (Con): Hearts were perfused with Krebs-Henseleit-Buffer (KHB) as vehicle for 10 min. Levosimendan 0.3 μM (Lev0.3): Hearts were perfused with 0.3 μM Lev for 10 min. Levosimendan 1 μM (Lev1): Hearts were perfused with 1 μM Lev for 10 min. Levosimendan 3 μM (Lev3): Hearts were perfused with 3 μM Lev for 10 min. Levosimendan 10 μM (Lev10): Hearts were perfused with 10 μM Lev for 10 min.
Figure 3. Experimental protocol. Con = Control; Lev = Levosimendan, KHB = Krebs-Henseleit-Buffer; Vehicle = Krebs-Henseleit Buffer (KHB). Green bar: Hearts were perfused with a total of 22 mmol/L glucose concentration by combining 11 mmol/L glucose solution with KHB (containing 11 mmol/L glucose). Control (Con): Hearts were perfused with Krebs-Henseleit-Buffer (KHB) as vehicle for 10 min. Levosimendan 0.3 μM (Lev0.3): Hearts were perfused with 0.3 μM Lev for 10 min. Levosimendan 1 μM (Lev1): Hearts were perfused with 1 μM Lev for 10 min. Levosimendan 3 μM (Lev3): Hearts were perfused with 3 μM Lev for 10 min. Levosimendan 10 μM (Lev10): Hearts were perfused with 10 μM Lev for 10 min.
Ijms 22 04517 g003
Ijms 22 04517 g004 550
Figure 4. Experimental protocol. Con = Control; Lev = Levosimendan, KHB = Krebs-Henseleit-Buffer; Vehicle = Krebs-Henseleit Buffer (KHB); CsA = Cyclosporine A (mPTP inhibitor). Green bar: Hearts were perfused with a total of 22 mmol/L glucose concentration by combining 11 mmol/L glucose solution with KHB (containing 11 mmol/L glucose). Control (Con): Hearts were perfused with Krebs-Henseleit-Buffer as vehicle for 10 min. Levosimendan 0.3 µM (Lev0.3): Hearts were perfused with 0.3 μM Lev for 10 min. Cyclosporine A (CsA): Hearts were perfused with 0.2 μM CsA for 10 min. Levosimendan 0.3 μM + Cyclosporine A (Lev0.3+CsA): Hearts were perfused with 0.3 μM Lev and 0.2 μM CsA for 10 min.
Figure 4. Experimental protocol. Con = Control; Lev = Levosimendan, KHB = Krebs-Henseleit-Buffer; Vehicle = Krebs-Henseleit Buffer (KHB); CsA = Cyclosporine A (mPTP inhibitor). Green bar: Hearts were perfused with a total of 22 mmol/L glucose concentration by combining 11 mmol/L glucose solution with KHB (containing 11 mmol/L glucose). Control (Con): Hearts were perfused with Krebs-Henseleit-Buffer as vehicle for 10 min. Levosimendan 0.3 µM (Lev0.3): Hearts were perfused with 0.3 μM Lev for 10 min. Cyclosporine A (CsA): Hearts were perfused with 0.2 μM CsA for 10 min. Levosimendan 0.3 μM + Cyclosporine A (Lev0.3+CsA): Hearts were perfused with 0.3 μM Lev and 0.2 μM CsA for 10 min.
Ijms 22 04517 g004
Table
Table 1. Weights and ischemic contracture.
Table 1. Weights and ischemic contracture.
nBody Weight
(g)		Heart
Weight Wet
(g)		Heart
Weight Dry
(g)		Time of Max.
Ischemic
Contracture
(min)		Level of Max. Ischemic Contracture (mmHg)
Part 1
HGCon7298 ± 81.21 ± 0.100.13 ± 0.0114 ± 185 ± 11
Lev0.37312 ± 71.22 ± 0.070.14 ± 0.0115 ± 282 ± 9
Lev17311 ± 141.28 ± 0.080.14 ± 0.0115 ± 175 ± 11
Lev37313 ± 171.32 ± 0.070.14 ± 0.0215 ± 182 ± 10
Lev107308 ± 131.22 ± 0.050.14 ± 0.0216 ± 165 ± 8 *
Part 2
HGCon5316 ± 111.27 ± 0.040.14 ± 0.0016 ± 275 ± 15
Lev0.35288 ± 211.24 ± 0.070.12 ± 0.0115 ± 279 ± 10
CsA5294 ± 241.15 ± 0.080.12 ± 0.0115 ± 277 ± 7
Lev0.3+CsA5307 ± 111.19 ± 0.040.12 ± 0.0115 ± 268 ± 8
Data are mean ± SD, HG = Hyperglycemia; Con = Control; Lev = Levosimendan; CsA = Cyclosporine A (mPTP inhibitor); * p < 0.05 vs. Con.
Table
Table 2. Hemodynamic variables Part 1.
Table 2. Hemodynamic variables Part 1.
BaselineReperfusion
304560
Heart Rate (bpm)
HGCon316 ± 43242 ± 41219 ± 57207 ± 69
Lev0.3307 ± 36255 ± 32228 ± 52267 ± 43
Lev1288 ± 38263 ± 109271 ± 83292 ± 40
Lev3278 ± 20231 ± 48208 ± 65214 ± 45
Lev10282 ± 20222 ± 64248 ± 86239 ± 79
Left Ventricular Developed Pressure (mmHg)
HGCon109 ± 927 ± 11 *35 ± 12 *33 ± 6 *
Lev0.3107 ± 1622 ± 14 *25 ± 9 *21 ± 10 *
Lev1117 ± 1713 ± 10 *20 ± 9 *20 ± 11 *
Lev3114 ± 1312 ± 12 *20 ± 14 *26 ± 7 *
Lev10122 ± 1112 ± 10 *19 ± 9 *25 ± 10 *
Coronary flow (mL/min)
HGCon12 ± 26 ± 1 *6 ± 1 *6 ± 1 *
Lev0.312 ± 36 ± 1 *6 ± 1 *6 ± 1 *
Lev113 ± 26 ± 1 *6 ± 1 *6 ± 1 *
Lev313 ± 26 ± 2 *7 ± 2 *6 ± 2 *
Lev1014 ± 38 ± 3 *8 ± 3 *8 ± 3 *
Data are mean ± SD. HG = Hyperglycemia; Con = Control; Lev = Levosimendan; * p < 0.05 vs. Baseline.
Table
Table 3. Hemodynamic variables Part 2.
Table 3. Hemodynamic variables Part 2.
BaselineReperfusion
304560
Heart Rate (bpm)
HGCon311 ± 54205 ± 42 *220 ± 69192 ± 16 *
Lev0.3297 ± 30245 ± 87259 ± 45216 ± 52
CsA292 ± 23215 ± 63214 ± 67229 ± 47
Lev0.3 + CsA306 ± 29297 ± 43267 ± 20265 ± 23
Left Ventricular Developed Pressure (mmHg)
HGCon117 ± 1920 ± 16 *28 ± 16 *28 ± 11 *
Lev0.3106 ± 1415 ± 13 *20 ± 19 *25 ± 16 *
CsA123 ± 2635 ± 8 *37 ± 13 *35 ± 10 *
Lev0.3 + CsA112 ± 2123 ± 18 *24 ± 13 *24 ± 12 *
Coronary flow (mL/min)
HGCon15 ± 37 ± 3 *6 ± 1 *6 ± 2 *
Lev0.313 ± 26 ± 1 *6 ± 1 *5 ± 1 *
CsA15 ± 25 ± 1 *6 ± 1 *6 ± 1 *
Lev0.3 + CsA14 ± 27 ± 2 *7 ± 2 *6 ± 1 *
Data are mean ± SD. HG = Hyperglycemia; Con = Control; Lev = Levosimendan; CsA = Cyclosporine A (mPTP inhibitor); * p < 0.05 vs. Baseline.
Table
Table 4. Glucose levels (mg/dL).
Table 4. Glucose levels (mg/dL).
BaselinePre
Ischemia		Reperfusion
15		Reperfusion
60
Part 1
HGCon196 ± 5370 ± 10 *394 ± 18 *425 ± 44 *
Lev0.3197 ± 6374 ± 37 *393 ± 11 *425 ± 28 *
Lev1197 ± 2360 ± 46 *389 ± 13 *409 ± 33 *
Lev3197 ± 4377 ± 10 *389 ± 32 *393 ± 41 *
Lev10198 ± 3372 ± 16 *377 ± 13 *400 ± 32 *
Part 2
HGCon203 ± 3384 ± 6 *389 ± 12 *418 ± 35 *
Lev0.3199 ± 9373 ± 16 *391 ± 9 *441 ± 18 *
CsA204 ± 10377 ± 9 *390 ± 10 *425 ± 20 *
Lev0.3 + CsA203 ± 6389 ± 8 *398 ± 5 *448 ± 35 *
Data are mean ± SD. HG = Hyperglycemia; Con = Control; Lev = Levosimendan; CsA = Cyclosporine A (mPTP inhibitor); * p < 0.05 vs. Baseline.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Torregroza, C.; Yueksel, B.; Ruske, R.; Stroethoff, M.; Raupach, A.; Heinen, A.; Hollmann, M.W.; Huhn, R.; Feige, K. Combination of Cyclosporine A and Levosimendan Induces Cardioprotection under Acute Hyperglycemia. Int. J. Mol. Sci. 2021, 22, 4517. https://doi.org/10.3390/ijms22094517

AMA Style

Torregroza C, Yueksel B, Ruske R, Stroethoff M, Raupach A, Heinen A, Hollmann MW, Huhn R, Feige K. Combination of Cyclosporine A and Levosimendan Induces Cardioprotection under Acute Hyperglycemia. International Journal of Molecular Sciences. 2021; 22(9):4517. https://doi.org/10.3390/ijms22094517

Chicago/Turabian Style

Torregroza, Carolin, Birce Yueksel, Raphael Ruske, Martin Stroethoff, Annika Raupach, André Heinen, Markus W. Hollmann, Ragnar Huhn, and Katharina Feige. 2021. "Combination of Cyclosporine A and Levosimendan Induces Cardioprotection under Acute Hyperglycemia" International Journal of Molecular Sciences 22, no. 9: 4517. https://doi.org/10.3390/ijms22094517

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop